Pay in 4 interest-free payments of $5.20 Learn more
Ships within 48 hours · Estimated delivery Sep 5 - Sep 10
In the SURPASS-2 trial, tirzepatide did not cause relevant changes in mean calcitonin levels
De Magalhes DA, Kume WT, Correia FS et al (2019) High-fat diet and streptozotocin in the induction of type 2 diabetes mellitus: a new proposal
Phase 3 trials of CagriSema demonstrated: 15.6% body weight loss with the combination versus 8.1% with semaglutide alone Superior glycemic control compared to either component individually Manageable side effect profile with proper dose titration Regulatory submissions completed in 2024 for obesity treatment [6] Since retatrutide includes GLP-1 receptor activation (similar to semaglutide) plus additional GIP and glucagon receptor effects, the theoretical cagrilintide blend with retatrutide could potentially exceed even the impressive CagriSema results
Three-Way Comparison: Retatrutide vs Tirzepatide vs Semaglutide Adding semaglutide provides context for the full generational progression of GLP-1 based therapies
US$ 25.57
US$ 20.85
US$ 26.23
US$ 23.84
US$ 28.85
